We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
-3.13%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$782M
AUM Growth
-$58.3M
Cap. Flow
-$21M
Cap. Flow %
-2.69%
Top 10 Hldgs %
99.98%
Holding
11
New
–
Increased
1
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$181K

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$18.1M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$1.98M
3
MRSN
Mersana Therapeutics
MRSN
+$1.11M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
1
Alkermes
ALKS
$8.22B
$253M 32.32%
8,964,640
– –
BIIB icon
2
Biogen
BIIB
$30B
$179M 22.86%
643,000
– –
IRWD icon
3
Ironwood Pharmaceuticals
IRWD
$696M
$172M 22.05%
16,390,000
– –
INVA icon
4
Innoviva
INVA
$1.55B
$74.4M 9.52%
6,614,000
– –
GILD icon
5
Gilead Sciences
GILD
$162B
$70.5M 9.02%
850,000
-218,750
-20% -$18.1M
MRSN
6
DELISTED
Mersana Therapeutics
MRSN
$15.6M 2%
152,000
-7,880
-5% -$1.11M
AMRN
7
Amarin Corp
AMRN
$299M
$7.37M 0.94%
245,500
+5,150
+2% +$181K
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$2.28B
$6.46M 0.83%
775,000
-205,288
-21% -$1.98M
VOR icon
9
Vor Biopharma
VOR
$1.15B
$3.32M 0.43%
30,900
– –
RGLS
10
DELISTED
Regulus Therapeutics
RGLS
$157K 0.02%
185,183
– –
PEAR
11
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
$128K 0.02%
500,356
– –

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Sarissa Capital Management held 11 positions worth $782M, down 6.9% from $840M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q1 2023: portfolio turnover was 0%. Sarissa Capital Management opened no new positions and made no exits, leaving the 11-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Sarissa Capital Management added most to Amarin Corp in Q1 2023, an estimated $181K increase.
  • Sarissa Capital Management's biggest Q1 2023 reduction was Gilead Sciences, cutting an estimated $18.1M.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $782M portfolio in Q1 2023.
  • Sarissa Capital Management opened 0 new positions and closed 0 in Q1 2023.
  • Sarissa Capital Management's portfolio value fell 6.9% quarter-over-quarter to $782M.

Based on Sarissa Capital Management's 13F filing for Q1 2023, filed 15 May 2023.